About: Antiviral Drugs Against Severe Fever With Thrombocytopenia Syndrome Virus Infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Antiviral Drugs Against Severe Fever With Thrombocytopenia Syndrome Virus Infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Antiviral Drugs Against Severe Fever With Thrombocytopenia Syndrome Virus Infection
Creator	Saijo, Masayuki Rong, Lijun Takayama-Ito, Mutsuyo Irie, Takashi Freiberg, Alexander
source	Medline; PMC
abstract	Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne infectious disease caused by SFTS virus (SFTSV), which is a novel bunyavirus. SFTSV was first isolated from patients who presented with fever, thrombocytopenia, leukocytopenia, and multiorgan dysfunction in China. Subsequently, it was found to be widely distributed in Southeast Asia (Korea, Japan, and Vietnam). SFTSV can be transmitted not only from ticks but also from domestic animals, companion animals, and humans. Because the case fatality rate of SFTS is high (6–30%), development of specific and effective treatment for SFTS is required. Studies of potential antiviral drugs for SFTS-specific therapy have been conducted on existing or newly discovered agents in vitro and in vivo, with ribavirin and favipiravir being the most promising candidates. While animal experiments and retrospective studies have demonstrated the limited efficacy of ribavirin, it was also speculated that ribavirin would be effective in patients with a viral load <1 × 10(6) copies/mL. Favipiravir showed higher efficacy than ribavirin against SFTSV in in vitro assays and greater efficacy in animal models, even administrated 3 days after the virus inoculation. Although clinical trials evaluating the efficacy of favipiravir in SFTS patients in Japan are underway, this has yet to be confirmed. Other drugs, including hexachlorophene, calcium channel blockers, 2′-fluoro-2′-deoxycytidine, caffeic acid, amodiaquine, and interferons, have also been evaluated for their inhibitory efficacy against SFTSV. Among them, calcium channel blockers are promising because in addition to their efficacy in vitro and in vivo, retrospective clinical data have indicated that nifedipine, one of the calcium channel blockers, reduced the case fatality rate by >5-fold. Although further research is necessary to develop SFTS-specific therapy, considerable progress has been achieved in this area. Here we summarize and discuss recent advances in antiviral drugs against SFTSV.
has issue date	2020-02-11(xsd:dateTime)
bibo:doi	10.3389/fmicb.2020.00150
bibo:pmid	32117168
has license	cc-by
sha1sum (hex)	78d5d3279bea15af4aaa52fe9b3302d52f657dc9
schema:url	https://doi.org/10.3389/fmicb.2020.00150
resource representing a document's title	Antiviral Drugs Against Severe Fever With Thrombocytopenia Syndrome Virus Infection
has PubMed Central identifier	PMC7026129
has PubMed identifier	32117168
schema:publication	Front Microbiol
resource representing a document's body	covid:78d5d3279bea15af4aaa52fe9b3302d52f657dc9#body_text
is schema:about of	named entity 'China' named entity 'inoculation' named entity 'interferons' named entity 'Favipiravir' named entity 'evaluating' named entity 'isolated' named entity 'companion animals' named entity 'ribavirin' named entity 'potential' named entity 'Fever' named entity 'Infection' named entity 'DEMONSTRATED' named entity 'CHINA' named entity 'VIRAL LOAD' named entity 'TRANSMITTED' named entity 'CAUSED BY' named entity 'ONE OF' named entity 'SEVERE FEVER WITH THROMBOCYTOPENIA SYNDROME' named entity 'NOVEL' named entity 'DAYS' named entity 'FAVIPIRAVIR' named entity 'CALCIUM CHANNEL BLOCKERS' named entity 'THERAPY' named entity 'COMPANION' named entity 'RECENT' named entity 'RETROSPECTIVE STUDIES' named entity 'EVALUATING' named entity 'HEXACHLOROPHENE' named entity 'AMODIAQUINE' named entity 'TICKS' named entity 'DEOXYCYTIDINE' named entity 'PROGRESS' named entity 'CAFFEIC ACID' named entity 'NIFEDIPINE' named entity 'DEVELOPMENT' named entity 'INOCULATION' named entity 'TREATMENT' named entity 'INTERFERONS' named entity 'HIGH' named entity 'VIETNAM' named entity 'VIRUS' named entity 'BEING' named entity 'ANIMAL MODELS' named entity 'OTHER DRUGS' named entity 'FOLD' named entity 'CLINICAL TRIALS' named entity 'DOMESTIC ANIMALS' named entity 'EFFECTIVE' named entity 'NEWLY DISCOVERED' named entity 'POTENTIAL' named entity 'JAPAN' named entity 'COPIES' named entity 'GREATER' named entity 'IN VITRO' named entity 'BUT' named entity 'THROMBOCYTOPENIA' named entity '30%' named entity 'IS A' named entity 'ANIMAL EXPERIMENTS' named entity 'RESEARCH' named entity 'PATIENTS' named entity 'DISCUSS' named entity 'EFFICACY' named entity 'LEUKOCYTOPENIA' named entity 'STUDIES' named entity '80%' named entity 'VIRUS INFECTION' named entity 'SEVERE FEVER WITH THROMBOCYTOPENIA SYNDROME VIRUS' named entity 'PRESENTED' named entity 'CONSIDERABLE' named entity 'BUNYAVIRUS' named entity 'LIMITED' named entity 'SPECIFIC' named entity 'HAVE' named entity 'TICK-BORNE INFECTIOUS DISEASE' named entity 'DISTRIBUTED' named entity 'FEVER'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software